GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » Return-on-Tangible-Equity

TLRY (Tilray Brands) Return-on-Tangible-Equity : -531.40% (As of Feb. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tilray Brands's annualized net income for the quarter that ended in Feb. 2025 was $-3,157.7 Mil. Tilray Brands's average shareholder tangible equity for the quarter that ended in Feb. 2025 was $594.2 Mil. Therefore, Tilray Brands's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2025 was -531.40%.

The historical rank and industry rank for Tilray Brands's Return-on-Tangible-Equity or its related term are showing as below:

TLRY' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3707.75   Med: -38.9   Max: 8.74
Current: -176.06

During the past 13 years, Tilray Brands's highest Return-on-Tangible-Equity was 8.74%. The lowest was -3,707.75%. And the median was -38.90%.

TLRY's Return-on-Tangible-Equity is ranked worse than
94.91% of 903 companies
in the Drug Manufacturers industry
Industry Median: 6.7 vs TLRY: -176.06

Tilray Brands Return-on-Tangible-Equity Historical Data

The historical data trend for Tilray Brands's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Return-on-Tangible-Equity Chart

Tilray Brands Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.26 -131.77 -190.73 -357.49 -57.53

Tilray Brands Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.97 -27.09 -29.06 -58.59 -531.40

Competitive Comparison of Tilray Brands's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Return-on-Tangible-Equity falls into.


;
;

Tilray Brands Return-on-Tangible-Equity Calculation

Tilray Brands's annualized Return-on-Tangible-Equity for the fiscal year that ended in May. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: May. 2024 )  (A: May. 2023 )(A: May. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: May. 2024 )  (A: May. 2023 )(A: May. 2024 )
=-244.981/( (333.064+518.553 )/ 2 )
=-244.981/425.8085
=-57.53 %

Tilray Brands's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Feb. 2025 )  (Q: Nov. 2024 )(Q: Feb. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Feb. 2025 )  (Q: Nov. 2024 )(Q: Feb. 2025 )
=-3157.744/( (605.688+582.776)/ 2 )
=-3157.744/594.232
=-531.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Tilray Brands  (NAS:TLRY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Tilray Brands Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands Business Description

Traded in Other Exchanges
Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Executives
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079